查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1579332

急性肺损伤治疗市场：按治疗类型、剂型、医疗保健提供者、诊断分类 - 2025-2030 年全球预测

Acute Lung Injury Treatment Market by Treatment Type (Non-Pharmacological Interventions, Pharmacotherapy, Surgical Intervention), Dosage Form (Inhalation, Injectable, Intravenous), Healthcare Provider, Diagnosis - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年急性肺损伤治疗市场规模为31亿美元，预计2024年将达32.2亿美元，复合年增长率为4.16%，2030年将达41.3亿美元。

急性肺损伤 (ALI) 治疗市场包括药品、医疗设备和旨在控制和缓解 ALI 患者症状的治疗方法，ALI 的特征是肺部广泛发炎迅速发作。 ALI 相关的高发病率和死亡率所需的治疗应用包括针对潜在病理学过程的通气支持和药物干预。最终用途范围主要包括专注于肺部健康的医院、诊所和研究机构，而此类治疗对于管理不同患者群体的急性呼吸窘迫至关重要。影响市场的关键成长要素包括肺炎、败血症和创伤等风险因素的日益流行，以及生物技术和再生医学的进步推动治疗通讯协定的创新。成长机会在于开发个人化医疗方法，利用先进的基因组学和生物标记识别来有效客製化治疗方法。此外，人工智慧和机器学习在诊断和治疗结果预测中的整合提供了另一个值得探索的沃土。

主要市场统计
基准年[2023] 31亿美元
预测年份 [2024] 32.2亿美元
预测年份 [2030] 41.3亿美元
复合年增长率（%） 4.16%

然而，由于目前的治疗方法通常是支持性的而不是治癒性的，缺乏具体的治疗方案和先进治疗方案的高成本限制了全球医疗保健系统，例如给该国带来了经济挑战。有关药物开发和核准的严格监管要求也可能阻碍市场成长。市场面临治疗效果的可变性和 ALI 复杂的病理学的挑战，这使得普遍有效的治疗方法的开发变得复杂。需要创新的领域包括发炎药物研究、干细胞治疗以及奈米技术在肺部标靶药物传递的应用。儘管有这些挑战，ALI 治疗市场仍充满活力，需要临床研究、生技公司和医疗保健提供者之间的合作，以优化治疗方法并改善患者的治疗结果。最终，适应监管环境和投资尖端研究对于企业的持续成长和市场领导地位至关重要。

市场动态：快速发展的急性肺损伤治疗市场的关键市场洞察

供需的动态交互作用正在改变急性肺损伤治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 急性肺损伤的盛行率不断增加，人们对早期诊断和治疗方案的认识不断提高
    • 政府和私人对医疗基础设施和肺部相关疾病研究进行了大量投资
    • 扩大非侵入性通气策略和个人化医疗在急性肺损伤治疗的采用
  • 市场限制因素
    • 核准新的急性肺损伤治疗方法的严格监管要求
  • 市场机会
    • 发展急性肺损伤治疗的个人化医疗方法，以改善患者的治疗效果
    • 利用人工智慧和机器学习进行急性肺损伤治疗和管理的预测分析
  • 市场挑战
    • 医疗保健专业人员和患者缺乏对急性肺损伤的认识和早期诊断

波特五力：开拓急性肺损伤治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解急性肺损伤治疗市场的外部影响

外部宏观环境因素在塑造急性肺损伤治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解急性肺损伤治疗市场的竞争格局

对急性肺损伤治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵急性肺损伤治疗市场供应商的绩效评估

FPNV 定位矩阵是评估急性肺损伤治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划急性肺损伤治疗市场的成功之路

对于希望加强在全球市场的影响力的公司来说，对急性肺损伤治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 急性肺损伤盛行率增加，人们对早期诊断和治疗方案的认识提高
      • 政府和私人对医疗基础设施和肺部相关疾病研究进行了大量投资
      • 在急性肺损伤的治疗中更多地采用非侵入性通气策略和个人化医疗
    • 抑制因素
      • 急性肺损伤新治疗方法的核准需要严格的监管要求
    • 机会
      • 发展急性肺损伤治疗的个人化医疗方法，以改善患者的治疗效果
      • 使用人工智慧和机器学习对急性肺损伤治疗进行预测分析和管理
    • 任务
      • 医护人员和病人缺乏对急性肺损伤的认识和早期诊断
  • 市场区隔分析
    • 治疗类型：

第 5 章 2.2。

  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依治疗类型分類的急性肺损伤治疗市场

  • 非药物干预
    • 体液管理
    • 通气辅助
  • 药物治疗
    • 抗生素
    • 皮质类固醇
    • 利尿剂
    • 黏液溶解药物
  • 手术介入
    • 支气管镜检查
    • 体外膜氧合（ECMO）
    • 肺移植

第七章依剂型分類的急性肺损伤治疗市场

  • 吸入
  • 可注射的
  • 静脉
  • 口服

第八章医疗保健提供者的急性肺损伤治疗市场

  • 诊所
    • 基层医疗诊所
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院
  • 调查机构
    • 政府研究中心
    • 大学医院

第九章 急性肺损伤诊断治疗市场

  • 验血
  • 支气管镜检查
  • 影像检查
    • 胸部X光检查
    • 电脑断层扫描
  • 氧气浓度测量

第十章美洲急性肺损伤治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区急性肺损伤治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲急性肺损伤治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准RYBREVANT 和 LAZCLUZE 合併用药代表 EGFR 突变肺癌治疗的重大进展
    • GSK 以 14 亿美元收购 Aiolos Bio，透过创新气喘治疗加强呼吸系统产品线
    • Aegis Therapeutics 从 BARDA 获得 2000 万美元，用于推进 ARDS 治疗的 2 期试验
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Bayer AG
  • BioLineRx Ltd.
  • Boehringer Ingelheim GmbH
  • Chiesi Farmaceutici SpA
  • CSL Behring LLC.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Ltd.
  • Lisata Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mesoblast Limited
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Synairgen plc
  • Takeda Pharmaceutical Company Limited
  • Windtree Therapeutics, Inc.
Product Code: MRR-1A1A064C0344

The Acute Lung Injury Treatment Market was valued at USD 3.10 billion in 2023, expected to reach USD 3.22 billion in 2024, and is projected to grow at a CAGR of 4.16%, to USD 4.13 billion by 2030.

The scope of the Acute Lung Injury (ALI) Treatment market encompasses pharmaceuticals, medical devices, and therapeutic modalities aimed at managing or alleviating symptoms in patients suffering from ALI, a condition characterized by rapid onset of widespread inflammation in the lungs. Necessitated by the high morbidity and mortality associated with ALI, treatment applications include ventilatory support and pharmaceutical interventions targeting the underlying pathophysiological processes. The end-use scope primarily involves hospitals, clinics, and research institutes focusing on pulmonary health, where such treatments are critical for managing acute respiratory distress in diverse patient demographics. Key growth factors influencing the market include increasing prevalence of risk factors such as pneumonia, sepsis, and trauma, coupled with advancements in biotechnology and regenerative medicine, which foster innovations in treatment protocols. Opportunities for growth lie in the development of personalized medicine approaches, leveraging advanced genomics and biomarker identification to tailor treatments effectively. Furthermore, the integration of AI and machine learning in predictive diagnostics and therapeutic outcomes presents another fertile area for exploration.

KEY MARKET STATISTICS
Base Year [2023] USD 3.10 billion
Estimated Year [2024] USD 3.22 billion
Forecast Year [2030] USD 4.13 billion
CAGR (%) 4.16%

However, limitations include a lack of specific treatment protocols, as current therapies are often supportive rather than curative, and the high cost of advanced therapeutic options poses economic challenges to healthcare systems globally. Stringent regulatory requirements for drug development and approval can also hinder market growth. The market faces challenges from variability in treatment responses and the complex pathogenesis of ALI, which complicates the development of universally effective treatments. Areas ripe for innovation include the research into anti-inflammatory drugs, stem-cell therapy, and the application of nanotechnology for targeted drug delivery to the lungs. Despite these challenges, the ALI treatment market is dynamic, with a forward-looking approach necessitating collaboration between clinical research, biotechnology firms, and healthcare providers to optimize treatment modalities and improve patient outcomes. Ultimately, navigating regulatory landscapes and investing in cutting-edge research are crucial for sustained business growth and market leadership.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acute Lung Injury Treatment Market

The Acute Lung Injury Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of acute lung injury and rising awareness about early diagnosis and treatment options
    • Significant government and private investments in healthcare infrastructure and research for lung-related diseases
    • Growing adoption of non-invasive ventilation strategies and personalized medicine to manage acute lung injury
  • Market Restraints
    • Strict regulatory requirements for approval of new acute lung injury treatments
  • Market Opportunities
    • Developing personalized medicine approaches for acute lung injury treatment to improve patient outcomes
    • Leveraging AI and machine learning for predictive analytics in acute lung injury treatment and management
  • Market Challenges
    • Lack of awareness and early diagnosis of acute lung injury among healthcare professionals and patients

Porter's Five Forces: A Strategic Tool for Navigating the Acute Lung Injury Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acute Lung Injury Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acute Lung Injury Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acute Lung Injury Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acute Lung Injury Treatment Market

A detailed market share analysis in the Acute Lung Injury Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acute Lung Injury Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acute Lung Injury Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acute Lung Injury Treatment Market

A strategic analysis of the Acute Lung Injury Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acute Lung Injury Treatment Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bayer AG, BioLineRx Ltd., Boehringer Ingelheim GmbH, Chiesi Farmaceutici S.p.A., CSL Behring LLC., Eli Lilly and Company, FibroGen, Inc., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Hoffmann-La Roche Ltd., Lisata Therapeutics, Inc., Merck & Co., Inc., Mesoblast Limited, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Synairgen plc, Takeda Pharmaceutical Company Limited, and Windtree Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Acute Lung Injury Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across Non-Pharmacological Interventions, Pharmacotherapy, and Surgical Intervention. The Non-Pharmacological Interventions is further studied across Fluid Management and Ventilatory Support. The Pharmacotherapy is further studied across Antibiotics, Corticosteroids, Diuretics, and Mucolytics. The Surgical Intervention is further studied across Bronchoscopy, Extracorporeal Membrane Oxygenation (ECMO), and Lung Transplant.
  • Based on Dosage Form, market is studied across Inhalation, Injectable, Intravenous, and Oral.
  • Based on Healthcare Provider, market is studied across Clinics, Hospitals, and Research Institutes. The Clinics is further studied across Primary Care Clinics and Specialized Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals. The Research Institutes is further studied across Government Research Centers and University Hospitals.
  • Based on Diagnosis, market is studied across Blood Tests, Bronchoscopy, Imaging Tests, and Oximetry. The Imaging Tests is further studied across Chest X-Ray and CT Scan.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of acute lung injury and rising awareness about early diagnosis and treatment options
      • 5.1.1.2. Significant government and private investments in healthcare infrastructure and research for lung-related diseases
      • 5.1.1.3. Growing adoption of non-invasive ventilation strategies and personalized medicine to manage acute lung injury
    • 5.1.2. Restraints
      • 5.1.2.1. Strict regulatory requirements for approval of new acute lung injury treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing personalized medicine approaches for acute lung injury treatment to improve patient outcomes
      • 5.1.3.2. Leveraging AI and machine learning for predictive analytics in acute lung injury treatment and management
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and early diagnosis of acute lung injury among healthcare professionals and patients
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type:

5.2.2. Diagnosis:

  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acute Lung Injury Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Non-Pharmacological Interventions
    • 6.2.1. Fluid Management
    • 6.2.2. Ventilatory Support
  • 6.3. Pharmacotherapy
    • 6.3.1. Antibiotics
    • 6.3.2. Corticosteroids
    • 6.3.3. Diuretics
    • 6.3.4. Mucolytics
  • 6.4. Surgical Intervention
    • 6.4.1. Bronchoscopy
    • 6.4.2. Extracorporeal Membrane Oxygenation (ECMO)
    • 6.4.3. Lung Transplant

7. Acute Lung Injury Treatment Market, by Dosage Form

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Injectable
  • 7.4. Intravenous
  • 7.5. Oral

8. Acute Lung Injury Treatment Market, by Healthcare Provider

  • 8.1. Introduction
  • 8.2. Clinics
    • 8.2.1. Primary Care Clinics
    • 8.2.2. Specialized Clinics
  • 8.3. Hospitals
    • 8.3.1. Private Hospitals
    • 8.3.2. Public Hospitals
  • 8.4. Research Institutes
    • 8.4.1. Government Research Centers
    • 8.4.2. University Hospitals

9. Acute Lung Injury Treatment Market, by Diagnosis

  • 9.1. Introduction
  • 9.2. Blood Tests
  • 9.3. Bronchoscopy
  • 9.4. Imaging Tests
    • 9.4.1. Chest X-Ray
    • 9.4.2. CT Scan
  • 9.5. Oximetry

10. Americas Acute Lung Injury Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Acute Lung Injury Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Acute Lung Injury Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA approval of RYBREVANT and LAZCLUZE combination offers significant advancement in EGFR-mutated lung cancer treatment
    • 13.3.2. GSK's USD 1.4 billion acquisition of Aiolos Bio boosts respiratory pipeline with innovative asthma treatment
    • 13.3.3. BioAegis Therapeutics secures USD 20 million from BARDA to advance phase 2 study for ARDS treatment
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Bayer AG
  • 3. BioLineRx Ltd.
  • 4. Boehringer Ingelheim GmbH
  • 5. Chiesi Farmaceutici S.p.A.
  • 6. CSL Behring LLC.
  • 7. Eli Lilly and Company
  • 8. FibroGen, Inc.
  • 9. Genentech, Inc.
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Hoffmann-La Roche Ltd.
  • 13. Lisata Therapeutics, Inc.
  • 14. Merck & Co., Inc.
  • 15. Mesoblast Limited
  • 16. Novartis International AG
  • 17. Pfizer Inc.
  • 18. Regeneron Pharmaceuticals, Inc.
  • 19. Sanofi S.A.
  • 20. Synairgen plc
  • 21. Takeda Pharmaceutical Company Limited
  • 22. Windtree Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. ACUTE LUNG INJURY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ACUTE LUNG INJURY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ACUTE LUNG INJURY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE LUNG INJURY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE LUNG INJURY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY FLUID MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY VENTILATORY SUPPORT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY MUCOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY LUNG TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY GOVERNMENT RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY UNIVERSITY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY BRONCHOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CHEST X-RAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CT SCAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY OXIMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 295. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HEALTHCARE PROVIDER, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY IMAGING TESTS, 2018-2030 (USD MILLION)
  • TABLE 306. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY NON-PHARMACOLOGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY PHARMACOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE ACUTE LUNG INJURY TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE ACUTE LUNG INJURY T